MGC Derma in UK market

AUSTRALIAN-LISTED cannabidiol (CBD) cosmetics and BioPharma group MGC Pharmaceuticals has announced via the ASX that its MGC Derma CBD based cosmetics collection will be sold on the ground floor of the

Beyond Beauty Department within Knightsbridge ( pictured) as well as through E-Commerce stores at luxury retailer Harvey Nichols, commencing from 29 Jun 2018.

MGC Derma is a joint venture with industry-credentialed cosmetics manufacturer, Dr. M. Burstein Ltd., operating in Europe, of which MGC Pharmaceuticals owns 51% and retains management control.

The MGC Derma and MGC Derma Plus collections, consisting of 18 products containing premium cannabidiol (CBD), will be available to consumers in store and online internationally, where legally permitted.

The highly anticipated launch is being supported by Harvey Nichols giving MGC the opportunity to immediately increase its revenue and build strategic brand awareness in a high end retail operation, the company said in its announcement.

The statement added that sales will also be driven by a targeted public relations and marketing campaign.

MGC Pharmaceuticals is continuing to develop capacity to meet the growing demand in the medicinal cannabis markets throughout Europe, North America and Australasia, the company said.